BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

With a broad, strategic suite of programs, Goldman Sachs views BioNTech as “being at the nexus of significant developments ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...

An update from BioNTech SE ( ($BNTX) ) is now available. On January 6, 2026, BioNTech SE reported that CureVac N.V. had completed a previously ...

BioNTech (NASDAQ:BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to ...

CureVac N.V. is a Germany-based biopharmaceutical company focused on the development of messenger RNA (mRNA)-based medicines, including vaccines and therapeutics, with its shares previously listed on ...

BioNTech SE will release its financial results for the second quarter of 2025 on August 4, 2025, and will hold a conference call and webcast that day at 8:00 a.m. EDT to discuss these results and ...

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb & Co. (NYSE:BMY) entered into a co-development and co-commercialization agreement. The pact focuses on BioNTech’s investigational bispecific antibody ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you. Good morning ...

BioNTech SE will announce its financial results for the first quarter of 2025 on May 5, 2025, and will hold a conference call and webcast at 8:00 a.m. EDT (2:00 p.m. CEST) to discuss these results and ...

MAINZ, Germany, May 21, 2024 – BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and ...